New binary solid dispersion of indomethacin and croscarmellose sodium: Physical characterization and in vitro dissolution enhancement.

Journal of Excipients and Food Chemicals

Volumn 3, Issue 4, 2012, Pages 121-128

  Castro, Silvina G ^a   Ramírez Rigo, María V ^b,c   Allemandi, Daniel A ^a   Palma, Santiago D ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

^c PLAPIQUI UNS CONICET   (Argentina)

Author keywords

Co processed material; Croscarmellose sodium; Dissolution rate; Indomethacin; Solid dispersions; Solid state characterization

Indexed keywords

CROSCARMELLOSE SODIUM; INDOMETACIN;

ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; IN VITRO STUDY; INFRARED SPECTROSCOPY; MELTING POINT; NONHUMAN; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; X RAY DIFFRACTION;

EID: 84871788372     PISSN: None     EISSN: 21502668     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Leuner C and Dressman J. Improving drug solubility for oral delivery using solid dispersions, Eur J Pharm Biopharm, 50: 47-60, 2000.
2. Amidon GL, Lennern̈as H, Shah VP and Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug 410 product dissolution and in vivo bioavailability. Pharm Res, 12: 413-420, 1995.
3. Chiou WL and Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci, 60: 1281-1302, 1971.
4. Deshpande OA and Yadav VB. Improvement in Physicochemical Properties of Indomethacin by Melt Granulation Technique. Int J Chem Tech Research, 1: 1312-1317, 2009.
5. Karavas E, Georgarakis E, Sigalas MP and Dimitrios Bikiaris KA. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur. J. Pharm Biopharm, 66: 334-347, 2007.
6. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today, 12: 1068-1075, 2007.
7. Shen TY, Lucas S, Sarett LH, Rosegray A, Nuss GW, Willett JD, Ellis RL, Holly FW, Matzuk AR, Wilson AN, Winter CA, Windholz TB, Risley EA, Stammer CH, Holtz WJ, Witzel BE. Nonsteroid antiinflammatory agents. J Am Chem Soc, 85: 488-489, 1963.
8. Winter CA, Risley EA, Nuss GW. Antiinflammatory and antipyretic activities of indomethacin, 1-(pchlorobenzoyl) 5-methoxy-2-methyl-indole-3-acetic acid. J Pharmacol Exp Ther, 141: 369-376, 1963.
9. Borka L. Polymorphism of indomethacin - new modifications, their melting behavior and solubility. Acta Pharm Suec, 11: 295-303, 1974.
10. Serajuddin ATM, Sheen P-C, Mufson D, Bernstein DF, Augustine MA. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J Pharm Sci, 77: 414-417, 1988.
11. Valizadeh H, Nokhodchi A. Qarakhani N, Zakeri Milani P, Azarmi S, Hassanzadeh D, Löbenberg R. Physicochemical Characterization of Solid Dispersions of Indomethacin with PEG 6000, Myrj 52, Lactose, Sorbitol, Dextrin, and Eudragit® E100. Drug Dev Ind Pharm, 30: 303-317, 2004.
12. Karmwar P, Graeser K, Gordon KC, Strachan CJ, Rades T. Investigation of properties and recrystal l i sation behaviour of amorphous indomethacin samples prepared by different methods. Int J Pharm, 417: 94- 100, 2011.
13. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm 293: 155-164, 2005.
14. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231: 131-144, 2002.
15. Collett, J.H. and Popli, H. Croscarmellose sodium. In: Handbook of Pharmaceutical Excipients; Kibbe, A.H. (ed), Pharmaceutical Press, London, pp. 211-213, 2000.
16. Moore J and Flanner H. Mathematical comparison of dissolution profiles. Pharm Technol, 20: 64-74, 1996.
17. Allen DJ and Kwan KC. Determination of degree of crystallinity in solid-solid equilibria. J Pharm Sci, 58: 1190-1193, 1969.
18. Yamamoto H. A new synthesis of 1-(pchlorobenzoyl)-5-methoxy-3-indolylacetic acid and its polymorphism. Chem Pharm Bull, 16: 17-19, 1968.
19. Ferris LA. Surface inhibited nucleation. A new method for the selective growth of stable drug polymorphs. Worcester Polytechnic Institute (2007). http://www.wpi.edu/Pubs/E-project/Available/E-project-042607-145921/unrestricted/Lori-A-Ferris-MQP-Final.pdf (accessed 01/05/2011)
20. Honary S, Majidian A, Naghibi F. The effect of different surfactants on the dissolution rate of recrystallized indomethacin. Iran J Pharm Res, 6: 25-33, 2007.
21. Slavin PA, Sheen DB, Shepherd EEA, Sherwood JN, Feeder N, Docherty R, Milojevic S. Morphological evaluation of the γ-polymorph of indomethacin. J Crystal Growth, 237-239: 300-305, 2002.
22. Andronis V and Zografi G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J Non-Cryst Solids, 271: 236-248, 2000.
23. Crowley KJ and Zografi G. Cryogenic Grinding of Indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci, 91: 492-507, 2002.
24. Atef E, Chauhan H, Prasad D, Kumari D and Pidgeon C., Quantifying solid-state mixtures of crystalline indomethacin by Raman Spectroscopy Comparison with Thermal Analysis, ISRN Chromatography, Article ID 892806: 1-6, 2012. DOI:10.5402/2012/892806
25. Srinarong P, Faber JH, Visser MR, Hinrichs WLJ, Frijilink HW. Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants. Eur J Pharm Biopharm, 73: 154-161, 2009.